Value Microcaps Free-For-All

[whyme2005]

NYER $2.14 REPORTS 3rd STRAIGHT PROFITABLE QUARTER.

NYER filed its 10Q AH today. The company posted its 3rd straight profitable..... 1c net income vs. 2c loss on increasing revenue. Keep in mind that this is seasonally the weakest quarter.

With 1.2M shares in the float, NYER should be a big gainer tomorrow. It gained as much as 35c after the filing was posted.

I expect an earnings PR tomorrow sometime before noon and not necessarily in the pre-market. The company is expected to announce expansion and growth plans in addition to its earnings results.

Keep an eye on this low-floater because it moves like a rocket!


MORE ON NYER:

* CONSISTENTLY PROFITABLE
* ULTRA LOW FLOAT - 1.2M SHARES
* STRONG BALANCE SHEET.
* MARKET CAP OF $8M
* REVENUES OF > $60M/YEAR
* P/S OF ONLY 0.13...SUPER UNDERVALUED!!!

Nyer Medical Group, Inc. is a holding company with operations in segments, including, pharmacies, medical and surgical equipment and supplies, and corporate. Through D.A.W., Inc., an 80%-owned subsidiary of the Company, it operates a chain of pharmacy drug stores in the suburban Boston, Massachusetts area. The Company's three wholly owned subsidiaries, ADCO Surgical Supply, Inc. (ADCO), ADCO South Medical Supplies, Inc. (ADCO South) and Nyer Internet Companies, Inc. (Internet) are engaged in the wholesale and retail sale of medical and surgical equipment and supplies throughout New England, Florida, Nevada and worldwide through the Internet sales.


OTHER GOOD STOCKS TO WATCH:

XNVA ($0.97)

Anti-smoking vaccines is are the hot topic of the day thanks to new visibility gained at ASCO this week. Cytos (from Zurich) reported excellent results for its anti-smoking vaccine candidate at this week's ASCO meetings. XNVA is one of only 3 companies with products in the pipeline to control smoking through a vaccine. XNVA is also working on a cocaine-anti-addiction vaccine. XNVA received a lot of front page mention in the last three days in Biz publications ranging from the NY Post to teh WSJ.

Unfortunately, you can't buy Cytos' shares...but you can buy XNVA's for under $1/share. Not for long though. XNVA is potentially a 10-bagger from this point on since it also has Transmid, a Phase III brain-cancer candidate, and many other significant medical developments.


WSCI ($2.81)

Profitable....1.2M float..pays quarterly dividends. Big earnings coming up. Company paid an equivalent of 16c/share the last two quarters for relocation costs to a newer/larger manufacturing plant. With those charges out of the way, net income is expected to range from 8 to 12c/share.

Do your DD on this one before irt is too late


EXXA ($1.52)

The company reported 4c/share net income last week. The next few quarters will be huge because the company won a multi-year $25M/yr + contract from DaimlerChrysler also last week:

http://biz.yahoo.com/prnews/050509/dam061.html?.v=4

It is hard to find info on this company. I had to have my broker enter the buy order for me. The symbol to enter in the order-entry form is EXX/A. One a positive note, EXXA has issued more PRs in a month than in the last two years combined. This could be a sign that the CEO (largest shareholder) wants a payoff for his patient accumulation of the last two years.

It is also hard to buy big chunks of stock. If you want to buy a few K, you'll have to pay over the ask. The MMs will throw you a bone for 100 to 300 shares at the bid every once in a while.

I expect that EXXA will report record revenues in 2Q and a hefty profit because of the DaimlerChrysler deal.

A few important facts about EXXA:

* LOW FLOAT = 4.7 MILLION SHARES
* 2004 REVENUES = $143 MILLION
* 2004 NET INCOME = $1.5 MILLION
* O/S SHARES = 11.3 MILLION
* MARKET CAP = $17 MILLION
* HEAVY INSIDER BUYING. INSIDERS OWN 54% OF COMPANY (Yahoo numbers are wrong...read the filings)



Always do your own DD.